114 related articles for article (PubMed ID: 37660640)
1. RSK4 confers paclitaxel resistance to ovarian cancer cells, which is resensitized by its inhibitor BI-D1870.
Nagumo Y; Villareal MO; Isoda H; Usui T
Biochem Biophys Res Commun; 2023 Oct; 679():23-30. PubMed ID: 37660640
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of RSK4 reverses doxorubicin resistance in human breast cancer cells via PI3K/AKT signalling pathway.
Mei Y; Liao X; Zhu L; Yang H
J Biochem; 2020 Jun; 167(6):603-611. PubMed ID: 31960922
[TBL] [Abstract][Full Text] [Related]
3. USP7 mediates TRAF4 deubiquitination to facilitate the malignant phenotype of ovarian cancer via the RSK4/PI3K/AKT axis.
Wang Y; Luo X; Wu N; Liao Q; Wang J
J Cancer Res Ther; 2023 Feb; 19(1):97-107. PubMed ID: 37006049
[TBL] [Abstract][Full Text] [Related]
4. Ribosomal S6 kinase 4 (RSK4) tumor suppressor gene promoter methylation status in ovarian cancer.
Arechavaleta-Velasco F; Dominguez-Lopez P; Acosta-Jimenez E; Diaz-Cueto L
Mol Biol Rep; 2023 Aug; 50(8):6863-6870. PubMed ID: 37402066
[TBL] [Abstract][Full Text] [Related]
5. Ribosomal S6 kinase 4 (RSK4) expression in ovarian tumors and its regulation by antineoplastic drugs in ovarian cancer cell lines.
Arechavaleta-Velasco F; Zeferino-Toquero M; Estrada-Moscoso I; Imani-Razavi FS; Olivares A; Perez-Juarez CE; Diaz-Cueto L
Med Oncol; 2016 Feb; 33(2):11. PubMed ID: 26732474
[TBL] [Abstract][Full Text] [Related]
6. Low expression of RSK4 predicts poor prognosis in patients with colorectal cancer.
Cai J; Ma H; Huang F; Zhu D; Zhao L; Yang Y; Bi J; Zhang T
Int J Clin Exp Pathol; 2014; 7(8):4959-70. PubMed ID: 25197367
[TBL] [Abstract][Full Text] [Related]
7. Regulation of replicative and stress-induced senescence by RSK4, which is down-regulated in human tumors.
López-Vicente L; Armengol G; Pons B; Coch L; Argelaguet E; Lleonart M; Hernández-Losa J; de Torres I; Ramon y Cajal S
Clin Cancer Res; 2009 Jul; 15(14):4546-53. PubMed ID: 19584160
[TBL] [Abstract][Full Text] [Related]
8. CPEB4-Promoted Paclitaxel Resistance in Ovarian Cancer
Zhang Y; Gan H; Zhao F; Ma X; Xie X; Huang R; Zhao J
Front Pharmacol; 2020; 11():600994. PubMed ID: 33519462
[No Abstract] [Full Text] [Related]
9. The effects of REG4 expression on chemoresistance of ovarian cancer.
Xiang LW; Xue H; Ha MW; Yu DY; Xiao LJ; Zheng HC
J Obstet Gynaecol; 2022 Oct; 42(7):3149-3157. PubMed ID: 35929918
[TBL] [Abstract][Full Text] [Related]
10. Prominent roles of ribosomal S6 kinase 4 (RSK4) in cancer.
Xu J; Jia Q; Zhang Y; Yuan Y; Xu T; Yu K; Chai J; Wang K; Chen L; Xiao T; Li M
Pathol Res Pract; 2021 Mar; 219():153374. PubMed ID: 33621918
[TBL] [Abstract][Full Text] [Related]
11. Epigallocatechin gallate and sulforaphane combination treatment induce apoptosis in paclitaxel-resistant ovarian cancer cells through hTERT and Bcl-2 down-regulation.
Chen H; Landen CN; Li Y; Alvarez RD; Tollefsbol TO
Exp Cell Res; 2013 Mar; 319(5):697-706. PubMed ID: 23333498
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Glutamine Uptake Resensitizes Paclitaxel Resistance in SKOV3-TR Ovarian Cancer Cell via mTORC1/S6K Signaling Pathway.
Kim G; Jang SK; Kim YJ; Jin HO; Bae S; Hong J; Park IC; Lee JH
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955892
[TBL] [Abstract][Full Text] [Related]
13. Gene expression profiles with cDNA microarray reveal RhoGDI as a predictive marker for paclitaxel resistance in ovarian cancers.
Goto T; Takano M; Sakamoto M; Kondo A; Hirata J; Kita T; Tsuda H; Tenjin Y; Kikuchi Y
Oncol Rep; 2006 May; 15(5):1265-71. PubMed ID: 16596196
[TBL] [Abstract][Full Text] [Related]
14. Effect of RSK4 on biological characteristics of colorectal cancer.
Ye Q; Wang X; Jin M; Wang M; Hu Y; Yu S; Yang Y; Yang J; Cai J
World J Surg Oncol; 2018 Dec; 16(1):240. PubMed ID: 30579335
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
16. Quantitative proteomic analysis of mitochondria from human ovarian cancer cells and their paclitaxel-resistant sublines.
Chen M; Huang H; He H; Ying W; Liu X; Dai Z; Yin J; Mao N; Qian X; Pan L
Cancer Sci; 2015 Aug; 106(8):1075-83. PubMed ID: 26033570
[TBL] [Abstract][Full Text] [Related]
17. Reversal of Chemoresistance in Ovarian Cancer by Co-Delivery of a P-Glycoprotein Inhibitor and Paclitaxel in a Liposomal Platform.
Zhang Y; Sriraman SK; Kenny HA; Luther E; Torchilin V; Lengyel E
Mol Cancer Ther; 2016 Oct; 15(10):2282-2293. PubMed ID: 27466355
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of circ_CELSR1 facilitates paclitaxel resistance of ovarian cancer by regulating miR-149-5p/SIK2 axis.
Wei S; Qi L; Wang L
Anticancer Drugs; 2021 Jun; 32(5):496-507. PubMed ID: 33735118
[TBL] [Abstract][Full Text] [Related]
19. Hypoxia-induced up-regulation of miR-27a promotes paclitaxel resistance in ovarian cancer.
Feng L; Shen F; Zhou J; Li Y; Jiang R; Chen Y
Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32190895
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-136 inhibits cancer stem cell activity and enhances the anti-tumor effect of paclitaxel against chemoresistant ovarian cancer cells by targeting Notch3.
Jeong JY; Kang H; Kim TH; Kim G; Heo JH; Kwon AY; Kim S; Jung SG; An HJ
Cancer Lett; 2017 Feb; 386():168-178. PubMed ID: 27887917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
